Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up

© 2024 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: https://jnm.snmjournals.org/page/permissions.

Author Information

Stefano Severi¹,
Ilaria Grassi¹,
Alberto Bongiovanni²,
Silvia Nicolini¹,
Irene Marini¹,
Donatella Arpa³,
Nicoletta Ranallo²,
Irene Azzali⁴,
Valentina Di Iorio⁵,
Anna Sarnelli⁶,
Monti Manuela⁴,
Elena Amadori⁷,
Lucia Fabbri³,
Daniela Bartolini⁸,
Luigino Tosatto⁹,
Francesco Di Meco¹⁰,¹¹,
Lorena Gurrieri²,
Nada Riva²,
Luana Calabro¹²,¹³,
Federica Matteucci¹,
Giovanni Paganelli¹ and
Maddalena Sansovini¹

¹Nuclear Medicine and Radiometabolic Units, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy;
²Osteoncology and Rare Tumor Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy;
³Radiotherapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Emilia Romagna, Italy;
⁴Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy;
⁵Oncological Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Emilia Romagna, Italy;
⁶Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy;
⁷Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy;
⁸Pathology Unit, “Maurizio Bufalini” Hospital, Cesena, Italy;
⁹Department of Neurosciences, Neurosurgery Division “M Bufalini” Hospital, Cesena, Emilia Romagna, Italy;
¹⁰Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy;
¹¹Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland;
¹²Department of Oncology, University Hospital of Ferrara, Cona, Italy; and
¹³Department of Translational Medicine, University of Ferrara, Ferrara, Italy